Amf Tjanstepension Ab Biomarin Pharmaceutical Inc Transaction History

Amf Tjanstepension Ab

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 05, 2023	SELL	$86.68 - $100.3 $1.48 Million - $1.71 Million	-17,023 Reduced 40.79%	24,714 $2.14 Million
Q4 2022 Jan 26, 2023	BUY	$80.93 - $108.63 $3.38 Million - $4.53 Million	41,737 New	41,737 $0
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $7.72 Million - $12.1 Million	-97,032 Closed	0 $0
Q1 2020 Apr 14, 2020	BUY	$71.37 - $96.85 $6.93 Million - $9.4 Million	97,032 New	97,032 $8.2 Million
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $14.8 Million - $17.4 Million	-176,236 Closed	0 $0
Q4 2018 Jan 30, 2019	SELL	$80.14 - $106.07 $6.08 Million - $8.05 Million	-75,910 Reduced 30.11%	176,236 $15 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $339,051 - $381,649	-3,610 Reduced 1.41%	252,146 $24.5 Million
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $3.18 Million - $4.15 Million	41,858 Added 19.57%	255,756 $24.1 Million
Q1 2018 May 10, 2018	SELL	$77.67 - $92.63 $1.07 Million - $1.28 Million	-13,771 Reduced 6.05%	213,898 $17.3 Million
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $2.45 Million - $2.89 Million	-30,392 Reduced 11.78%	227,669 $20.3 Million
Q3 2017 Nov 08, 2017	BUY	$80.6 - $94.95 $20.8 Million - $24.5 Million	258,061	258,061 $24 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Amf Tjanstepension Ab, based on Form 13F filings with the SEC.

Stay updated on Amf Tjanstepension Ab with notifications on news.